These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Liposomal drug formulations in cancer therapy: 15 years along the road. Slingerland M; Guchelaar HJ; Gelderblom H Drug Discov Today; 2012 Feb; 17(3-4):160-6. PubMed ID: 21983329 [TBL] [Abstract][Full Text] [Related]
3. Novel cytotoxic drugs: old challenges, new solutions. Ismael GF; Rosa DD; Mano MS; Awada A Cancer Treat Rev; 2008 Feb; 34(1):81-91. PubMed ID: 17905518 [TBL] [Abstract][Full Text] [Related]
4. Molecular imaging as a tool for personalized and targeted anticancer therapy. McLarty K; Reilly RM Clin Pharmacol Ther; 2007 Mar; 81(3):420-4. PubMed ID: 17339871 [No Abstract] [Full Text] [Related]
5. Review: new biological insights in early clinical studies. Maur M; Sessa C Hematol Oncol; 2007 Jun; 25(2):53-7. PubMed ID: 17351979 [TBL] [Abstract][Full Text] [Related]
6. Finding the right dose for cancer therapeutics--can we do better? Rubin EH; Anderson KM Clin Cancer Res; 2010 Feb; 16(4):1085-7. PubMed ID: 20145182 [TBL] [Abstract][Full Text] [Related]
7. Use of systemic antineoplastic drug therapy after regulatory agency approval. Markman M Oncology; 2007; 72(3-4):145-6. PubMed ID: 18087174 [No Abstract] [Full Text] [Related]
8. Oral delivery of anticancer drugs I: general considerations. Mazzaferro S; Bouchemal K; Ponchel G Drug Discov Today; 2013 Jan; 18(1-2):25-34. PubMed ID: 22951365 [TBL] [Abstract][Full Text] [Related]
9. A first-in-human study of conatumumab in adult patients with advanced solid tumors. Herbst RS; Kurzrock R; Hong DS; Valdivieso M; Hsu CP; Goyal L; Juan G; Hwang YC; Wong S; Hill JS; Friberg G; LoRusso PM Clin Cancer Res; 2010 Dec; 16(23):5883-91. PubMed ID: 20947515 [TBL] [Abstract][Full Text] [Related]
10. Marijuana as an antiemetic drug: how useful is it today? Opinions from clinical oncologists. Schwartz RH; Beveridge RA J Addict Dis; 1994; 13(1):53-65. PubMed ID: 7503819 [TBL] [Abstract][Full Text] [Related]
11. First-time-in-man and pharmacokinetic study of weekly oral perifosine in patients with solid tumours. Unger C; Berdel W; Hanauske AR; Sindermann H; Engel J; Mross K Eur J Cancer; 2010 Mar; 46(5):920-5. PubMed ID: 20079628 [TBL] [Abstract][Full Text] [Related]
17. Phase I clinical trial to determine maximum tolerated dose of oral albendazole in patients with advanced cancer. Pourgholami MH; Szwajcer M; Chin M; Liauw W; Seef J; Galettis P; Morris DL; Links M Cancer Chemother Pharmacol; 2010 Feb; 65(3):597-605. PubMed ID: 19904538 [TBL] [Abstract][Full Text] [Related]
18. Diagnostics in cancer drug development. Sikora K Expert Rev Mol Diagn; 2004 Mar; 4(2):127-9. PubMed ID: 14995899 [No Abstract] [Full Text] [Related]
19. Voreloxin, a first-in-class anticancer quinolone derivative, in relapsed/refractory solid tumors: a report on two dosing schedules. Advani RH; Hurwitz HI; Gordon MS; Ebbinghaus SW; Mendelson DS; Wakelee HA; Hoch U; Silverman JA; Havrilla NA; Berman CJ; Fox JA; Allen RS; Adelman DC Clin Cancer Res; 2010 Apr; 16(7):2167-75. PubMed ID: 20233886 [TBL] [Abstract][Full Text] [Related]
20. Drug approval triggers debate on future direction for cancer treatments. Frantz S Nat Rev Drug Discov; 2006 Feb; 5(2):91. PubMed ID: 16521324 [No Abstract] [Full Text] [Related] [Next] [New Search]